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Abstract
Background Gamma Knife radiosurgery (GKRS) has been proven to be a successful primary treatment for metastatic brain
tumors (BM). BM can come in cystic lesions and are often too large for GKRS. An alternative approach to treat cystic BM is
stereotactic cyst aspiration (SCA) for volume reduction, making it suitable for GKRS afterwards.
Objective Our objective is evaluation of volumetric reduction after SCA, tumor control, and complications after SCA directly
followed by GKRS.
Methods We performed a retrospective analysis of all patients who underwent SCA directly followed byGKRS at the GammaKnife
Center of the Elisabeth-Tweesteden Hospital in Tilburg between 2002 and 2015. In total, 54 patients had undergone this combined
approach. Two patients were excluded because of prior intracranial treatment. The other 52 patients were included for analysis.
Results SCA resulted in a mean volumetric reduction of 56.5% (range 5.50–87.00%). In 83.6% of the tumors (46 tumors), SCA led to
sufficient volumetric reduction making GKRS possible. The overall local tumor control (OLTC) of the aspirated lesions post-GKRS
was 60.9% (28 out of 46 tumors). Median progression-free survival (PFS) and overall survival (OS) for all patients were 3 (range
5 days–14 months) and 12 months (range 5 days–58 months), respectively. Leptomeningeal disease was reported in 5 (9.6%) cases.
Conclusion SCA directly followed by GKRS is an effective and time-efficient treatment for large cystic BM in selected patients
in which surgery is contraindicated and those with deeply located lesions.
Keywords Stereotactic cyst aspiration . GammaKnife radiosurgery . Cystic brain metastases . Ommaya reservoir
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Introduction
The incidence of brain metastasis (BM) in cancer patients
ranges between 20 and 40% [16, 17]. Gamma Knife radiosur-
gery (GKRS) has been proven to be a successful primary
treatment for metastatic brain tumors. On the other hand,
GKRS has its own limitations. It is not suitable for large tu-
mors, especially for tumors > 3 cm in diameter [6, 8]. In case
of large cystic metastasis, surgery is the first choice of treat-
ment for these metastases. However, surgery may be contra-
indicated in some patients because of deep and eloquent cyst
location, important co-morbidity, advanced age, and patient
preference. An alternative approach is stereotactic cyst aspira-
tion (SCA) to reduce the volume, making it suitable for GKRS
afterwards. In this study, we describe a patient cohort, in
which SCA is directly followed by GKRS on the same day.
Our objective is evaluation of volumetric reduction after SCA,
tumor control, and complications after reducing cyst aspira-
tion followed by GKRS.
Methods and materials
Between June 10, 2002, and March 31, 2015, a total of 2842
procedures were performed at our center for patients with BM.
Fifty-four of these procedures were planned for upfront SCA
followed by GKRS on the same day for 57 large cystic me-
tastases. The diagnosis was based on MRI findings. Pre- and
post-treatment clinical characteristics were reviewed. We in-
cluded all patients who never had any prior intracranial treat-
ment and had a minimal cyst volume of 9 cc. Two patients
were excluded because of previous intracranial treatment (one
GKRS; one resection followed by craniospinal radiotherapy).
The preoperative physical state was scored according to the
ASA (American Society of Anesthesiologists) grading sys-
tem. All patients included were ASA IV. A total of 52 patients
were included with 20 of these patients having solitary cystic
metastases and 32 patients with additional lesions (cystic or
non-cystic). Two of the 32 patients had only 2 cystic metasta-
ses (both lesions underwent SCA), and a third patient had 2
cystic lesions (both underwent SCA) with multiple non-cystic
lesions. Eventually, a total of 55 large cystic metastases were
planned for SCA followed by GKRS on the same day. Cystic
fluid aspirated during SCA procedure was sent for histopath-
ological evaluation.
All cases were retrospectively analyzed. Therefore, there
was no need for ethical approval by the ethics committee. All
patients were classified according to the recursive partitioning
analysis (RPA) classification system of the Radiation Therapy
Oncology Group (RTOG) [18]. The included patients
consisted of 20 males and 32 female, with a median age of
61 (range 36–83 years). The most frequent primary tumor was
non-small cell lung cancer (NSCLC) followed by breast
cancer (BC) with the majority of the BM located in the
supratentorial region. Other pre-treatment patient characteris-
tics are summarized in Table 1. Pre- and post-SCA tumor
volume was measured with the Leksell GammaPlan
Software (Elekta).
Treatment procedure
The SCAwas performed under local anesthesia in the operat-
ing theater. Prior to the SCA, the application of the Leksell
Table 1 Pre-treatment patients characteristics
Characteristics No. of
patient
Median Range
Gender
Male 20
Female 32
Age (years) 61 36–83
KPS sore 80 50–100
RPA classification
Class 1 11
Class 2 34
Class 3 7
Primary tumor
NSCLC 34
Breast cancer 7
Colorectal cancer 4
Oesophageal cancer 1
Endometrium cancer 1
Ovarian cancer 1
Bladder cancer 1
Parotid cancer 1
PTU 2
Location of cystic lesions
Supratentorial 36
Infratentorial 19
Solitary cystic lesions 20
Multiple cystic and non-cystic lesions 32
Number of metastases 2 1–9
1 20
2 11
3 10
≥ 4 11
Pre-aspiration tumor volume (cc) 26.9 9.97–111.50
Synchronous metastasis 15
Metachronous metastasis 35
PTU 2
NSCLC, non-small cell carcinoma; KPS, Karnofsky performance status;
RPA, recursive partitioning analysis; PTU, primary tumor unknown
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stereotactic frame was performed using a local anesthetic so-
lution. Following frame placement, MRI was obtained, and
the patient was transferred to the operating room. This SCA
procedure is navigation-based whereby the biopsy needle is
fixed on a stereotactic biopsy device attached to the Leksell
stereotactic frame. The path for the aspiration needle was de-
termined using the Leksell Surgiplan® software. Immediately
after SCA, the patients were transferred to the Gamma Knife
Center for subsequent radiosurgery.
The GKRS procedure was performed using the Leksell
Gamma Knife 4C, before 2009, and Leksell Gamma Knife
Perfexion thereafter. Following SCA, high-resolution stereo-
tactic MRI (1.5 Tesla) was performed for treatment planning.
Pre- and post-contrast (triple-dose gadolinium) T1 weighted
axial images were obtained with a slice thickness of 1.5 mm.
Stereotactic radiosurgery and dose planningwas performed by
a team of a neurosurgeon, radiation oncologist, and medical
physicist. The target was defined as the contrast enhancing
lesions on the planning MRI. The median number of metas-
tases treated with GKRS was 2 (range 1–9) with a mean/
median tumor volume of 6.5 cc/6.2 cc (range 0.001–
43.504 cc). The prescribed dose ranged between 20 and
25 Gy (median 20 Gy), depending on the size and location
of the tumor. The dose was prescribed to the isodoseline cov-
ering 99% of the target.
After completion of the treatment, patients were admitted
to the ward for 1-day observation. After GKRS, follow-up
(FU) including MRIs was performed at 6 weeks, 3 months
after treatment, and thereafter every 3 months as long as clin-
ically meaningful. Treatment-associated complications were
documented.
Definitions
Overall intracranial tumor control: Freedom from any kind of
progression (reaccumulation of cystic fluid, and/or local tu-
moral tissue progression, and/or occurrence of distant lesions)
until the end of FU.
Overall local tumor control of aspirated lesions: This in-
cludes freedom from any local progression (reaccumulation of
cystic fluid and/or tumoral tissue progression).
Overall local tumoral tissue control of aspirated lesions:
This includes freedom from tumoral tissue progression but
does not include freedom from reaccumulation of cystic fluid.
Statistical analysis
All statistical analyses were performed using IBM SPSS sta-
tistics version 23. Kaplan–Meier curve was plotted to deter-
mine tumor control, overall survival, and progression-free
survival.
Results
Volumetric reduction after SCA
Prior to SCA, the mean/median tumor volume was 35.3 cc/
31.3 cc (range 10.0–111.5 cc). The mean/median post-SCA
volume was 14.2 cc/12.7 cc (range 4.2–47.0 cc). This resulted
in a mean volumetric reduction of 56.4% (range 5.5–87.0%)
(Fig. 1). In 83.6% of the tumors (46 tumors, mean/median
volume of 11.2 cc/9.3 cc, range 4.2–15.0 cc), SCA led to
sufficient volumetric reduction making it possible to undergo
GKRS. The cutoff point for undergoing GKRS was 15 cc
(equivalent to the volume of a 3-cm diameter sphere). The
median PD was 20 (range 20–25 Gy).
Those patients not eligible for GKRS after SCA underwent
a second stage craniotomy, radiation therapy, or a combination
of both (Table 2).
Complications after SCA
Complications occurred in 3 patients (5.8%) which resulted in
death of 2 patients. One died due to pneumocephalus and
another due to epidural bleeding. The third patient developed
a cerebral vascular accident (CVA) after 1 month of FU. This
third patient stopped its anticoagulant therapy (acetylsalicylic
acid) before the procedure and restarted it after 1 week. No
seeding occurred in any patients during FU.
Fig. 1 Effect cyst aspiration on
tumor volume
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Tumor control by GKRS
GKRS could take place in 46 (83.6%) cystic tumors. After
GKRS, the overall intracranial tumor control was 53.3% (24
out of 45 patients).
The overall local tumor control of the aspirated cystic le-
sions after GKRS was 60.9% (28 out of 46 tumors). Seven
(15.2%) of these lesions demonstrated only reaccumulation of
cystic fluid, four (8.7%) demonstrated reaccumulation of cys-
tic fluid in combination with tumoral tissue progression, and
seven (15.2%) demonstrated only tumoral tissue progression.
All these patients received additional treatment. Thus, the
overall local tumoral tissue control of aspirated lesions was
76.1% (35 out 46 tumors). No significant difference was
shown in those who received a PD of > 20 (log rank test;
p = 0.54). When there only was reaccumulation of cystic fluid
and no local tumor progression, patients received salvage
treatment in the form of a second SCA (4 patients) alone or
SCAwith Ommaya reservoir (3 patients) placement (ORP). In
case of tumoral tissue progression, patients received anti-
tumoral therapy (Table 2). The overall local tumor control of
the small non-aspirated lesions was 100%. Distant progres-
sion occurred in 15 (29%) patients after a median FU time
of 7 months (range 1–36 months). Seeding did not occur in
any of the patients. Leptomeningeal disease was reported in 5
(9.6%) cases after a median FU time of 6 months (range 3–
7 months). No GKRS-related complications occurred.
Kaplan–Meier curve of the local tumor control of the aspirated
lesions is shown in Fig. 2.
Adverse events
Adverse events were scored according to the CTCAE (CTC-
M) version 4.0. Forty patients (77%) had no adverse events.
Frame-related swelling occurred in 9.6% (5 out of 52) of the
patients within a median time of 10 days. Headache (grade I)
occurred in 3 patients (5.8%) and focal alopecia (grade I) in 4
patients (7.6%). No serious adverse events were noted after
GKRS.
Survival
A total of 43 patients died during FU. Nine patients (20.9%)
died due to intracranial disease, 22 (51.2%) due to extracranial
disease, and 12 (27.9%) due to intra- and extracranial disease.
Median progression-free survival (PFS) and overall survival
(OS) for all patients were 3 (range 5 days–14 months) and
12 months (range 5 days–58 months), respectively (Fig. 2).
Neurology
Pre-SCA symptoms were headache (20 patients, 38%), focal
motor deficit (16 patients, 31%), and ataxia (16 patients,
31%). Improvement of symptoms occurred in all patients
(100%) immediately after the SCA. The neurological control
(freedom from neurological progression) was 100%, 77%,
73%, 70%, and 54% at 2, 4, 6, 8, and 10 months of FU,
respectively. At a median FU time of 12 months, the neuro-
logical control had dropped to 34%.
Histopathology
The nature of the aspirated content was analyzed by the pa-
thology department. In 37 cases, only the cyst fluid was aspi-
rated and in 18 cases the cyst aspiration was accompanied
with biopsy of the cyst wall. In 78% of the cases that
underwent cyst aspiration in combination with biopsy, the
diagnosis could be confirmed versus 54% in those that only
underwent cyst aspiration (Table 3).
Two types of fluids were obtained in patients undergoing
the stereotactic aspiration. These types of fluid were yellowish
turbid and yellowish transparent. The turbid fluid contained
much more tumor cells, necrotic cells, and macrophages in
comparison with the transparent fluid (Table 3).
Discussion
Gamma Knife radiosurgery has established itself as a power-
ful tool for the treatment of BM. However, BM can come in
cystic lesions often too large for GKRS. Another important
aspect is that cystic BM tends to have a less good reaction to
radiosurgery [2, 14]. Conventionally, single large cystic BM
has been regarded as an indication for surgery since it can
provide rapid relief of neurological symptoms caused by the
mass effect [2, 21]. However, if these lesions are located deep
within the brain or in eloquent areas, surgery may result in
severe neurological deficit. In addition, patients in poor gen-
eral condition or with multiple lesions are not suitable for
surgery. An alternative approach is to make these tumors
Table 2 Second treatment after failed SCA and tumoral tissue
progression
Second treatment No. of patients
Second treatment after failed SCA
Craniotomy 3
RT 3
Craniotomy + postoperative WBRT 1
Craniotomy + postoperative RT 1
Second treatment after tumoral tissue progression
SCA + ORP followed by GKRS 4
GKRS 7
RT, radiotherapy;WBRT, whole brain radiotherapy; SCA, stereotactic cyst
aspiration; ORP, Ommaya reservoir placement; GKRS, Gamma Knife
radiosurgery
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Fig. 2 a Kaplan–Meier curve of
the local tumor control. b
Kaplan–Meier curve of the
progression-free survival. c
Kaplan–Meier curve of the over-
all survival
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suitable for GKRS by reducing the volume via SCA.
Combination of these two procedures into one treatment
makes it possible to treat large cystic metastases with GKRS
in patients not fit for craniotomy. Thus, we designed a se-
quence of procedures in which SCA is immediately followed
by GKRS on the same day. Using the same Leksell stereotac-
tic frame for both procedures allows a seamless flow from
SCA to GKRS in 1 day, reducing the physical and psycholog-
ical burden for the patient. Another advantage of this 1-day
approach is to minimize the time window within which the
cyst reaccumulates fluid and thus avoiding the need for con-
tinuous aspiration through an Ommaya reservoir (OR). The
goal of this type of treatment is to obtain mass reduction with a
relatively small surgical procedure and thus relieve of neuro-
logic symptoms in combination with radiation-induced cell
death without damaging surrounding neuronal tissue.
SCA is an important first procedure. The volumetric
decrease will determine whether a patient is eligible for
GKRS. The cutoff point was set at 15 cc after SCA which
is equivalent to the volume of a 3-cm diameter sphere.
This is in line with others setting a cutoff point between
16.0 and 16.6 cc [3, 19].
In this study, SCA led to 83.6% of the tumors (46 tumors)
to sufficient volumetric reduction making it possible to under-
go GKRS.
The mean volumetric decrease was 56.5% after SCAwhich
is within the range of other studies reporting a mean volumet-
ric decrease of 47.8–77.9% [2, 3, 5, 15] after SCA. A great
advantage of cyst aspiration is acute symptomatic relief due to
mass reduction. Immediate improvement of symptoms oc-
curred in all patients (100%) following drainage. This imme-
diate neurological improvement after SCA was also reported
by others [9, 13, 15, 19].
An important question is whether an OR placement during
SCA can have additional value since reaccumulation of cystic
fluid after GKRS occurred in 23.9% of the lesions (11 out of
46 tumors).
Park et al. reported a mean volumetric decrease of 77.9%
[15]. The reason for this high rate of reduction is because 48%
of the lesions were treated with additional OR insertion after
SCA. In 2006, Yamanaka et al. placed an OR during cyst
aspiration followed by GKRS up to 60 days later [20]. This
two-step approach may be more feasible for most centers but
is more uncomfortable for patients since this treatment takes
more time and may increase the risk of fluid reaccumulation
during the waiting period. However, an advantage of ORP in
addition to SCA is when during the GKRS planning MRI a
tumor volume is seen still too large for GKRS one can under-
go immediate additional subcutaneous cyst aspiration via the
reservoir to obtain a sufficient reduction in volume. This ap-
proach of ORP during SCA is to be seriously considered in
our center due to its practicality and since it can serve as an
additional tool for sufficient reduction in volume prior and
after GKRS in case of fluid reaccumulation without the need
for a second surgical procedure. Thus, it can serve as tumor
control and relieve of neurological symptoms. This may have
prevented surgery in our patients not eligible for GKRS after
SCA and in those needing a second SCA or ORP after GKRS
(Table 2). However, ORP during SCA should only be consid-
ered for very large lesions following removal of clear-fluid
content. In case of turbid fluid, the chance of the tube remain-
ing patent is probably low.
Complications related to the SCA are relatively rare.
Possible complications include hemorrhage, neurological def-
icits, seizures, and infections [10]. The mortality rate in large
series has been less than 1%, and the complication rates vary
from 0–7% [1, 10]. This is in line with our study reporting a
complication rate of 5.8%. Unfortunately two patients died in
this study due to SCA-related complications: one due to
pneumocephalus and the other due to an epidural bleeding
resulting in a mortality rate of 3.8%. This is a high mortality
rate and does not evoke enthusiasm. However, one should
bear in mind that there is a selection bias since the study
population are all ASA IV. These patients have a higher
peri- and postoperative complication rate and thus a higher
Table 3 Pathological evaluation of the aspirated fluid content
Procedure No. of tumors No. of PA confirmation
of primary tumor
SCA alone 37 20 (54%)
Type of cells
Tumor cells 20 (54%)
Macrophages 18 (49%)
Histiocytes 2 (5%)
Necrotic cells 16 (43%)
SCA + biopsy 18 14 (78%)
Type of cells
Tumor cells 14 (78%)
Macrophages 3 (17%)
Histiocytes 2 (11%)
Necrotic cells 12 (67%)
Fluid type
Orange/yellowish turbid 31
Tumor cells 25 (80%)
Macrophages 13 (42%)
Histiocytes 2 (6%)
Necrotic cells 20 (65%)
Orange/yellowish transparent 14
Tumor cells 7 (50%)
Macrophages 3 (21%)
Histiocytes 2 (14%)
Necrotic cells 8 (57%)
SCA, stereotactic cyst aspiration
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mortality risk. Another explanation is the relative small num-
ber of patients included in the study. Increasing the study
population will result in a lower mortality rate.
There is a theoretical risk for tumor cell seeding along the
aspiration needle tract. However, the incidence of seeding is
poorly described in the literature after SCA. Seeding is mainly
described in studies performing stereotactic needle biopsy.
Karlsson et al. reported tumor cell seeding in 9% of the pa-
tients treated with GKRS for BM in whom biopsy specimens
were obtained via stereotactic needle biopsy prior to the
radiosurgical treatment [7]. In our study, seeding did not occur
in any of the patients.
Tumor control is an important aspect of this treatment. The
overall local tumor control of the aspirated cystic lesions after
GKRS was 60.9%, which is within the range of other studies
reporting a tumor control of 54.2–91.7% [2, 3, 5, 9, 15, 19,
20]. The local tumor progression was 39.1% which is in line
with others reporting a local tumor progression of 8.3–41.4%
[2, 3, 5, 9, 15, 19, 20]. Distant progression was 29% whereas
others reported distant progression of 16.7–52.2% [2, 15, 19].
The mean tumor volume of the aspirated cystic lesions under-
going GKRS was 11.168 cc (range 4.210–14.950 cc). The
median PD was 20 Gy (range 20–25 Gy). Larger tumors re-
ceived a lower dose (20 Gy). This may account for higher
rates of tumor recurrence. Leptomeningeal disease was report-
ed in 9.6% of the cases. Others observed leptomeningeal dis-
semination of 14.2% after GKRS [12]. Franzin et al. reported
that 7.6% of the patients experienced radionecrosis after ste-
reotactic aspiration followed by SCA of cystic BM [2]. In our
study, no radiation necrosis was seen in any of the patients
during FU.
Stereotactic radiotherapy (SRT) can be a good alternative
option in patients with large cystic tumors after SCA. SRT
can be used for optimizing radiation dose to large residual cystic
tumors. Ikushima et al. reported amedian survival of 4.3months
in patients undergoing SRT, which is far lower compared with
those who underwent SRS (25.6 months) or surgery in combi-
nation with postoperative SRT (18.7 months) [4].
The overall median survival in this study was 12 months.
Others reported similar median overall survival rates ranging
from 6.8–19.5 months [2, 3, 5, 9, 15, 19, 20]. Tendulkar et al.
reported a median survival of 8.7 months in those undergoing
subtotal resection for single brain metastasis and 10.6 months
after gross total resection (GTR) [18]. Although it is difficult
to compare these results with ours, the results of GKRS after
SCA of large cystic BM were as good as that of GTR.
Therefore, SCA followed by GKRS could be a better treat-
ment option instead of surgical resection for cystic tumors
located in deep or eloquent areas within the brain. Another
well-known treatment option is surgery followed by WBRT.
In 2008, a randomized controlled trial showed that this treat-
ment resulted in a median survival time of 9.5 months which is
comparable with our study [11].
Histopathological analysis was done on the aspirated cystic
fluid. The turbid fluid contained, as expected, much more tu-
mor cells, necrotic cells, and macrophages compared with the
transparent fluid. Cyst aspiration in combination with biopsy of
the cyst wall resulted in 78% of the case confirmation of the
histopathological diagnosis compared with 54% in those that
only underwent cyst aspiration. To increase the chance of his-
topathological confirmation of the diagnosis, cyst aspiration in
combination of biopsy of the cyst wall is advised.
Study limitations
This is a single center retrospective study with a relatively small
number of patients and is therefore subjected to biases (selec-
tion bias and treatment bias) and limitations. Major limitations
are non-protocolized treatment regimens. All patients received
systemic treatment prior to GKRS. The treatment included the
use of chemotherapeutic agents, and heterogeneity in primary
tumors. Therefore, the group we present is heterogeneous
which makes comparison to historical groups difficult.
Conclusion
This study shows that SCA results in sufficient volumetric
decrease of cystic BM in a high percentage of the cases, mak-
ing these lesions suitable for GKRS. Reduction of the volume
permits higher radiation doses and is associated with lower
risk of post-radiation complications. This 1-day aspiration
followed by GKRS is less invasive than resection but should
be used for selected patients whose overall condition is too
poor to undergo microsurgery and in those with deeply locat-
ed lesions or multiple lesions, since SCA can be associated
with significant complications.
An Ommaya reservoir placement during SCA is recom-
mended since it can serve as an additional tool to obtain suf-
ficient volumetric decrease in case of fluid reaccumulation
avoiding the need for a second surgical procedure.
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